Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).


Clinical Trial Description

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD). Subjects will sign consent form prior to any study related procedure and will complete screening assessments. Subjects will be randomized to either the treatment group or the placebo group at a ratio of 1:1. The study will be conducted in two parts. Titration period On Day 1, subjects will complete all baseline assessments prior to the 1st dosing. Pramipexole group: Consenting individuals meeting accession criteria will start pramipexole 2.0mg daily dose (1.0mg twice a day) with ondansetron 16mg daily dose (8mg twice a day). Pramipexole will be titrated up daily or every two days depends on each patients' tolerability up to the first intolerable dose (FID) or maximum allowed dose (5 mg/day) according to titration schedule (Table 1). Once subjects reach their FID, their maximum allowed dose (MTD) will be defined as 1 mg below their FID. During titration, subjects will be admitted to the clinic (subjects will be discharged on the day following their pramipexole FID or Day 8 if subjects reach to 5 mg/day of pramipexole. Placebo group will take 3 placebo tablets twice a day. Maintenance period During the maintenance phase, patients will be treated with pramipexole MTD or MAD with ondansetron 16mg/day for the remainder of the 8-week treatment. Placebo group is taking 3 tablets of placebo twice a day during the trial. Exit visit After the Week 8 visit, study medications will be discontinued, and subject will return for Exit visit at Week 9. After the Exit visit, all subjects will return to their prior treatment for depression or started on a new therapeutic regimen as medically appropriate. At study completion (or at other times in accordance with Stopping Rules given below), and all study participants will return to their pre-admission therapeutic regimen or started on a new therapeutic regimen as medically appropriate. Higher doses of pramipexole IR may be tapered off at rates deemed medically appropriate by PI. In this modified single blind study, efficacy raters will be kept unaware of the participants' treatment status. An independent data and safety monitoring board (DSMB) will be appointed to have responsibility for safeguarding the interests of the trial subjects and assessing the safety and tolerability of the study treatments during the trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03642964
Study type Interventional
Source Chase Therapeutics Corporation
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 10, 2018
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Completed NCT05416957 - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Phase 1
Terminated NCT01111565 - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT01912196 - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT00958204 - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression Phase 3
Completed NCT00102492 - Study Of GW679769 In Major Depressive Disorder Phase 2
Completed NCT02012218 - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Phase 3
Completed NCT01477203 - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders Phase 4
Completed NCT00768430 - Optimization of IV Ketamine for Treatment Resistant Depression Phase 2
Completed NCT00559299 - Patient Tolerability Study of GSK163090 Phase 1
Terminated NCT01123707 - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT04403373 - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study N/A
Completed NCT05541302 - Retrospective TMS Therapy for Adults With MDD
Completed NCT00330616 - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan Phase 2
Recruiting NCT03012724 - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) N/A
Completed NCT02380066 - Comparison of Anyu Peibo With Placebo in Treatment of MDD Phase 2
Not yet recruiting NCT02395263 - Comparison of Yuxintine With Placebo in Treatment of MDD Phase 2
Completed NCT01187407 - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment Phase 3
Completed NCT00448292 - A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder Phase 2
Completed NCT00057239 - An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder Phase 2